{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:54:07Z","timestamp":1761008047940,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vascn.2022.107213","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:27:20Z","timestamp":1662510440000},"page":"107213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma's experience and perspective"],"prefix":"10.1016","volume":"118","author":[{"given":"Eric D.","family":"Watt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyun Lily","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kilfoil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ackley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Keefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Wisialowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Anon","key":"10.1016\/j.vascn.2022.107213_bb0005"},{"key":"10.1016\/j.vascn.2022.107213_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107114","article-title":"Use of automated patch clamp in cardiac safety assessment: Past, present & future perspectives","volume":"111","author":"Bell","year":"2021","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"13","key":"10.1016\/j.vascn.2022.107213_bb0015","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for Drug Proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Reports"},{"issue":"6","key":"10.1016\/j.vascn.2022.107213_bb0020","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","volume":"321","author":"Cardiac Arrhythmia Suppression Trial, I","year":"1989","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.vascn.2022.107213_bb0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199207233270403","article-title":"Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction","volume":"327","author":"Cardiac Arrhythmia Suppression Trial, I. I. I","year":"1992","journal-title":"The New England Journal of Medicine"},{"issue":"23","key":"10.1016\/j.vascn.2022.107213_bb0030","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochemical Pharmacology"},{"author":"CiPA","key":"10.1016\/j.vascn.2022.107213_bb0035"},{"key":"10.1016\/j.vascn.2022.107213_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2022.107213_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2022.107213_bb0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740338.2013.780026","article-title":"Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia","volume":"12","author":"Doggrell","year":"2013","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.vascn.2022.107213_bb0055","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fphys.2017.00616","article-title":"Optimization of an in silico cardiac cell model for Proarrhythmia risk assessment","volume":"8","author":"Dutta","year":"2017","journal-title":"Frontiers in Physiology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107213_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro Proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"Journal of Biomolecular Screening"},{"issue":"202","key":"10.1016\/j.vascn.2022.107213_bb0065","first-page":"61133","article-title":"International conference on harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability","volume":"70","author":"Food & Drug Administration, H. H. S","year":"2005","journal-title":"Federal Register"},{"issue":"5","key":"10.1016\/j.vascn.2022.107213_bb0070","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/0735-1097(92)90267-Q","article-title":"The cardiac arrhythmia suppression Trial: First CAST \u2026 Then CAST-II","volume":"19","author":"Greene","year":"1992","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1016\/j.vascn.2022.107213_bb0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2022.107213_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174584","article-title":"Characterization of a high throughput human stem cell cardiomyocyte assay to predict drug-induced changes in clinical electrocardiogram parameters","volume":"912","author":"Kilfoil","year":"2021","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2022.107213_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2022.107213_bb0090","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41598-020-62344-w","article-title":"Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells","volume":"10","author":"Kramer","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.vascn.2022.107213_bb0095","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: Superior to the HERG model in predicting torsade de pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Scientific Reports"},{"author":"Kuhn","key":"10.1016\/j.vascn.2022.107213_bb0100"},{"issue":"4","key":"10.1016\/j.vascn.2022.107213_bb0105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpt.367","article-title":"Improved prediction of drug-induced Torsades de pointes through simulations of dynamics and machine learning algorithms","volume":"100","author":"Lancaster","year":"2016","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2022.107213_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the in silico assessment of Proarrhythmia risk by combining hERG (human ether-a-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107213_bb0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/cpt.1647","article-title":"General principles for the validation of Proarrhythmia risk prediction models: An extension of the CiPA in silico strategy","volume":"107","author":"Li","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2022.107213_bb0120","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for Proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2022.107213_bb0125","first-page":"12","article-title":"Classification and regression by randomForest","volume":"2","author":"Liaw","year":"2002","journal-title":"R News"},{"issue":"1","key":"10.1016\/j.vascn.2022.107213_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk","volume":"91","author":"Mirams","year":"2011","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2022.107213_bb0135","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4352","article-title":"Complex versus simple models: Ion-channel cardiac toxicity prediction","volume":"6","author":"Mistry","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.vascn.2022.107213_bb0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fphar.2015.00059","article-title":"A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment","volume":"6","author":"Mistry","year":"2015","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10.1016\/j.vascn.2022.107213_bb0145","article-title":"Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation","volume":"7","author":"O\u2019Hara","year":"2011","journal-title":"PLoS Computational Biology"},{"issue":"3","key":"10.1016\/j.vascn.2022.107213_bb0150","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2006.04.075","article-title":"Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database","volume":"48","author":"Pratt","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"author":"R-Project","key":"10.1016\/j.vascn.2022.107213_bb0155"},{"issue":"3","key":"10.1016\/j.vascn.2022.107213_bb0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11538-021-00982-5","article-title":"A quantitative systems pharmacology perspective on the importance of parameter identifiability","volume":"84","author":"Sher","year":"2022","journal-title":"Bulletin of Mathematical Biology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107213_bb0165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9149(86)90958-6","article-title":"The cardiac arrhythmia pilot study. The CAPS investigators","volume":"57","author":"The CAPS investigators","year":"1986","journal-title":"The American Journal of Cardiology"},{"author":"Woosley","key":"10.1016\/j.vascn.2022.107213_bb0170"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:05:37Z","timestamp":1761005137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871922000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":34,"alternative-id":["S1056871922000600"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107213","relation":{},"ISSN":["1056-8719"],"issn-type":[{"type":"print","value":"1056-8719"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma's experience and perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107213"}}